These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29439419)

  • 1. Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives.
    Mercatelli D; Bortolotti M; Bazzocchi A; Bolognesi A; Polito L
    Biomedicines; 2018 Feb; 6(1):. PubMed ID: 29439419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody Conjugates for Sarcoma Therapy: How Far along Are We?
    Polito L; Calafato G; Bortolotti M; Chiarelli Olivari C; Maiello S; Bolognesi A
    Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.
    Roth M; Barris DM; Piperdi S; Kuo V; Everts S; Geller D; Houghton P; Kolb EA; Hawthorne T; Gill J; Gorlick R
    Pediatr Blood Cancer; 2016 Jan; 63(1):32-8. PubMed ID: 26305408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Billups CA; Hawthorne T; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2014 Oct; 61(10):1816-21. PubMed ID: 24912408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies.
    Slemmons KK; Mukherjee S; Meltzer P; Purcell JW; Helman LJ
    Pediatr Blood Cancer; 2021 Feb; 68(2):e28771. PubMed ID: 33063919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.
    Kopp LM; Malempati S; Krailo M; Gao Y; Buxton A; Weigel BJ; Hawthorne T; Crowley E; Moscow JA; Reid JM; Villalobos V; Randall RL; Gorlick R; Janeway KA
    Eur J Cancer; 2019 Nov; 121():177-183. PubMed ID: 31586757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Therapy With Immunoconjugates for Multiple Myeloma.
    Bruins WSC; Zweegman S; Mutis T; van de Donk NWCJ
    Front Immunol; 2020; 11():1155. PubMed ID: 32636838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the treatment of hematologic malignancies using immunoconjugates.
    Palanca-Wessels MC; Press OW
    Blood; 2014 Apr; 123(15):2293-301. PubMed ID: 24578502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
    Ott PA; Pavlick AC; Johnson DB; Hart LL; Infante JR; Luke JJ; Lutzky J; Rothschild NE; Spitler LE; Cowey CL; Alizadeh AR; Salama AK; He Y; Hawthorne TR; Bagley RG; Zhang J; Turner CD; Hamid O
    Cancer; 2019 Apr; 125(7):1113-1123. PubMed ID: 30690710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE).
    Vaklavas C; Forero A
    BioDrugs; 2014 Jun; 28(3):253-63. PubMed ID: 24496926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
    Yardley DA; Weaver R; Melisko ME; Saleh MN; Arena FP; Forero A; Cigler T; Stopeck A; Citrin D; Oliff I; Bechhold R; Loutfi R; Garcia AA; Cruickshank S; Crowley E; Green J; Hawthorne T; Yellin MJ; Davis TA; Vahdat LT
    J Clin Oncol; 2015 May; 33(14):1609-19. PubMed ID: 25847941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer.
    Keir CH; Vahdat LT
    Expert Opin Biol Ther; 2012 Feb; 12(2):259-63. PubMed ID: 22229970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted drug delivery using immunoconjugates: principles and applications.
    Pasquetto MV; Vecchia L; Covini D; Digilio R; Scotti C
    J Immunother; 2011; 34(9):611-28. PubMed ID: 21989410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.
    Bendell J; Saleh M; Rose AA; Siegel PM; Hart L; Sirpal S; Jones S; Green J; Crowley E; Simantov R; Keler T; Davis T; Vahdat L
    J Clin Oncol; 2014 Nov; 32(32):3619-25. PubMed ID: 25267761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.
    Rose AAN; Biondini M; Curiel R; Siegel PM
    Pharmacol Ther; 2017 Nov; 179():127-141. PubMed ID: 28546082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives.
    Nicolò E; Giugliano F; Ascione L; Tarantino P; Corti C; Tolaney SM; Cristofanilli M; Curigliano G
    Cancer Treat Rev; 2022 May; 106():102395. PubMed ID: 35468539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads.
    Boni V; Sharma MR; Patnaik A
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-17. PubMed ID: 32315240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-drug conjugates for urothelial carcinoma.
    Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
    Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of immunoconjugates for targeted cancer therapy.
    Smaglo BG; Aldeghaither D; Weiner LM
    Nat Rev Clin Oncol; 2014 Nov; 11(11):637-48. PubMed ID: 25265912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antibody-drug conjugates as new therapeutic agents in uro-oncology].
    Grimm MO; Foller S; Leeder M; Leucht K
    Urologie; 2023 Jul; 62(7):679-684. PubMed ID: 37294330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.